Key facts
- Youkaize Biopharmaceuticals’s last known valuation is $137.9M (Feb 2025).
- It has raised $11.0M; the latest was Seed Round ($11.0M) in Feb 2025.
- Notable investors include CARsgen Therapeutics.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Youkaize Biopharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Youkaize Biopharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Youkaize Biopharmaceuticals
Developer and provider of universal CAR-T cell therapies designed for the treatment of hematologic cancers. The company provides innovative biopharmaceutical research and development, enabling hematologic cancer patients with effective and safe treatment solutions.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2024
- Ownership
- Privately Held (backing)
Youkaize Biopharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Youkaize Biopharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Youkaize Biopharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.